Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS Rating: 5.03, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.03 new
Vol. 9, Issue 6 (2020)

Avoiding warning letters in pharmaceutical industry: A qualitative study in the Indian context

Author(s):
Sanjay Kumar Jain and Rajesh Kumar Jain
Abstract:
The purpose of this paper is to identify the cause and effect of increased number of warning letters (www.fda.gov) issued by the Food and Drug Administration (FDA) of United States year after year in spite of clarity in the guidance published by the agency. Increased number of warning letters is matter of concern for the drug product / drug substance manufacturer, drug authority and end consumers (patients). Author identified six pharma professionals through their personal contacts and interviewed each of them. Poor quality management systems and lack of management oversight were found to be the key reasons for issuance of warning letters. Issuance of warning letters had adverse financial impact on business, delay in approvals thus loss of business opportunity and negative image of the organization among regulators, customers. Quality culture in the organization plays an important role to ensure regulatory compliance and building up the right quality culture in the organization is vital. Involvement of top management and participation in the management review meetings is essential for monitoring the compliance level in the organization.
Pages: 18-24  |  126 Views  7 Downloads
How to cite this article:
Sanjay Kumar Jain, Rajesh Kumar Jain. Avoiding warning letters in pharmaceutical industry: A qualitative study in the Indian context. Pharma Innovation 2020;9(6):18-24. DOI: 10.22271/tpi.2020.v9.i6a.4767
The Pharma Innovation Journal